In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Six-month outcomes from the transcatheter tricuspid valve repair multicentre TRI-REPAIR trial

Session Heart failure prognosis and the options to improve

Speaker Francesco Maisano

Event : Heart Failure 2018

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Valvular Heart Disease – Treatment
  • Session type : Rapid Fire Abstracts

Authors : A Latib (Milan,IT), G Nickenig (Bonn,DE), RS Von Bardeleben (Mainz,DE), J Hausleiter (Munich,DE), U Schafer (Hamburg,DE), KH Kuck (Hamburg,DE), S Baldus (Koln,DE), JM Juliard (Paris,FR), A Vahanian (Paris,FR), F Maisano (Zurich,CH)

A Latib1 , G Nickenig2 , RS Von Bardeleben3 , J Hausleiter4 , U Schafer5 , KH Kuck6 , S Baldus7 , JM Juliard8 , A Vahanian8 , F Maisano9 , 1San Raffaele Hospital (IRCCS) - Milan - Italy , 2University Hospital Bonn - Bonn - Germany , 3University Medical Center of Mainz - Mainz - Germany , 4University Hospital of Munich - Munich - Germany , 5University Heart Center Hamburg - Hamburg - Germany , 6Asklepios Clinic St. Georg - Hamburg - Germany , 7Heart Center University of Köln - Koln - Germany , 8Hospital Bichat-Claude Bernard - Paris - France , 9University Hospital Zurich - Zurich - Switzerland ,


Background: The Edwards Cardioband™ Valve Reconstruction System enables transcatheter repair to address patients with mitral or tricuspid regurgitation. The safety and performance in the treatment of functional mitral regurgitation have been validated in the CE mark trial.

Purpose: to report up to 6 months follow-up results from the first 30 patients included in the study designed to assess safety, feasibility and efficacy in the treatment of functional tricuspid regurgitation (FTR).

Methods: Between October 2016 and July 2017, thirty patients with severe symptomatic FTR were enrolled among 9 participating sites in Europe. All patients were screened by the heart teams of the local sites and underwent thorough pre-procedural echocardiography and cardiac computed tomography evaluation. Echocardiographic data were assessed by an independent core lab.

Results: Mean patient age was 75.2 years, 73.3% were females, 23.3% had ischemic heart disease and the mean EuroSCORE II was 4.1%. At baseline, 83.3% of patients were in NYHA functional class III-IV and LVEF was 57.5%. Successful access, deployment and positioning was achieved in 100% of the patients. There were two deaths at one month follow-up. Implant size adjustment resulted in an average reduction of septolateral tricuspid annular diameter of 16.5% (4.43±0.44cm to 3.7±0.45cm; p<0.01) at discharge.

Thirty-day follow-up is available for 28 patients. 82.2% of patients were in NYHA class I-II. Echocardiography compared to baseline showed reduction in PISA EROA of 51% (from 0.79±0.5 cm2 to 0.39±0.3 cm2, p<0.001) and a 28% reduction in mean vena contracta (from 1.25±0.4 cm to 0.9±0.4 cm, p<0.001).

Six month follow-up is currently available for 22 patients. 85.7% of patients were in NYHA class I-II.  Compared to baseline, there was a significant improvement in 6 minute walk test from 278.4 m to 327.4 m, (p<0.05), and a decrease in the occurrence of peripheral edema from 76% to 48% (p=0.06).  Echocardiography showed significant reduction in PISA EROA of 48% (from 0.73±0.5 cm2 to 0.38±0.2 cm2, p<0.05) and a 27% reduction in mean vena contracta (from 1.1±0.3 cm to 0.8±0.3 cm, p<0.001).

Conclusions: Outcomes up to 6-months suggest feasibility and safety of transcatheter tricuspid repair with the Cardioband Tricuspid System in patients with symptomatic TR. Significant annular reduction and reduction of tricuspid regurgitation was observed despite treating a large proportion of patients with "torrential" TR at baseline. The study is ongoing and further follow-up data are warranted to validate the initial promising results.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are